GEN-003
Phase 2Biologic
GEN-003 is one of 13 biologic programs targeting Genital Herpes. It is currently in Phase 2.
1
Indications
5
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Genital Herpes
#DrugCompanyPhaseTrials
1Famvir
NovartisApproved
Zovirax
BBp Consulting, Inc
Approved
Valaciclovir
GSKApproved
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 3
Herpes Zoster Vaccine 1437173a
GSKPhase 3
Aciclovir
SanofiPhase 3
ASP2151
AstellasPhase 2
Bexsero
GSKPhase 2
AIC316
AAiCuris Anti-infective Cures AG
Phase 2
GEN-003
GGenocea Biosciences, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GEN-003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- GGenocea Biosciences, Inc.